Hawryluk P. Kent 4
4 · MBX Biosciences, Inc. · Filed Sep 17, 2024
Insider Transaction Report
Form 4
Hawryluk P. Kent
DirectorPresident & CEO
Transactions
- Conversion
Series A Convertible Preferred Stock
2024-09-16−2,015,681→ 0 total→ Common Stock (167,664 underlying) - Conversion
Series C Convertible Preferred Stock
2024-09-16−970,873→ 0 total(indirect: By Trust)→ Common Stock (80,757 underlying) - Conversion
Common Stock
2024-09-16+115,914→ 398,277 total(indirect: By Trust) - Conversion
Common Stock
2024-09-16+283,846→ 481,397 total - Conversion
Series A Convertible Preferred Stock
2024-09-16−345,705→ 0 total(indirect: By Trust)→ Common Stock (28,755 underlying) - Conversion
Series B Convertible Preferred Stock
2024-09-16−1,396,762→ 0 total→ Common Stock (116,182 underlying) - Conversion
Series B Convertible Preferred Stock
2024-09-16−76,969→ 0 total(indirect: By Trust)→ Common Stock (6,402 underlying)
Footnotes (2)
- [F1]Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
- [F2]Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.